相关实验视频
Updated: Jun 25, 2025

07:47
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
Published on: January 9, 2016
15.4K
关于药物开发延迟一天的成本的新估计
Zachary P Smith1, Joseph A DiMasi2, Kenneth A Getz2
1Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA. zachary.smith605922@tufts.edu.
Therapeutic innovation & regulatory science
|May 21, 2024
概括
错过一天的临床研究成本约为50万美元的药品销售损失,但平均每日销售额下降了. 每天的临床试验平均花费4万美元,在特定治疗领域的费用更高.
科学领域:
- 制药研发领域的研究和开发.
- 临床试验的管理管理.
- 卫生经济学 卫生经济学
背景情况:
- 关于每日处方药销售和临床试验成本的已确定的数字已经过时和事.
- 准确的财务数据对于药物开发中有效的资源配置至关重要.
研究的目的:
- 提供最新的经验估计,对处方药销售延迟一天的财务影响.
- 确定与进行II期和III期临床试验相关的当前每日直接成本.
- 分析随着时间的推移,每处方药和生物药的平均每日销售趋势.
主要方法:
- 分析了自2000年以来推出的645种药物和409种临床试验预算.
- 利用商用和专有数据集进行实证研究.
- 在2023年底进行了研究,以收集详细的财务估计.
主要成果:
- 错过处方药或生物销售的单一天相当于大约50万美元的收入损失.
- 每日处方销售额最高的是传染病,血液病,心血管和胃肠道疾病.
- 每种药物的平均每日销售额每年下降了8万至10万美元.
- 第二期和第三期临床试验的每日直接成本平均为4万美元.
- 呼吸系统,风湿学和皮肤病学试验的相对每日直接成本最高.
结论:
- 药物开发和临床试验延迟的财务影响是巨大的.
- 新药和生物制剂的平均每日销售量呈下降趋势.
- 准确的成本效益分析需要为临床研究和药物开发提供最新的财务数据.
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Drug Administration and Therapy Phases: Overview
448
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
448
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84

